Biosimilars

This is the second in our series of posts based on the OHE seminar on biosimilars and summarises the remarks of Prof Bengt Jönsson of the Stockholm School of Economics.

The availability of biosimilars -- ‘copies’ of biologics -- is very recent and limited so far to only a few products. Projecting the impact on markets of the appearance of ‘biosimilars’ is still difficult, both for individual products and for the market as a whole. This the first in a series of blog posts about the issues, as discussed at an OHE-sponsored seminar.

Pages

Subscribe to RSS - Biosimilars